Current concepts in the prevention of Alzheimer's disease

被引:13
作者
Sano, M
机构
[1] Vet Affairs Med Ctr, Bronx, NY 10468 USA
[2] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA
[3] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA
关键词
D O I
10.1017/S1092852900019283
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease represents a significant challenge to the aging population. Since most estimates suggest that AD has a multifactorial etiology, the challenge to find preventative approaches is particularly great. With the aging of the population and the very high incidence from the eighth decade on, the challenge is further enhanced by the need to think of relatively safe interventions given the relative frailty of this elderly population. The need to find safe treatments, or ones with well-understood safety profiles, has led to the examination of known agents for potential dementia-preventing properties. Data supporting these interventions comes from observational studies, laboratory analyses I and clinical trials. Potential mechanisms for prevention of AD include and-inflammatory and antioxidant approaches. Modulation of risk factors associated with cardiac disease may also reduce the risk of AD. Known agents have been examined for their potential to modify amyloid pathology. Trial designs to address prevention of AD include both primary and secondary prevention studies as well designs to assess slowing disease progression. Information can also be gathered when dementia evaluation is added to ongoing studies. As results from these studies becoming available, we will be able to refine our approach to managing this disease.
引用
收藏
页码:846 / 853
页数:8
相关论文
共 58 条
  • [1] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
    Aisen, PS
    Schafer, KA
    Grundman, M
    Pfeiffer, E
    Sano, M
    Davis, KL
    Farlow, MR
    Jin, S
    Thomas, RG
    Thal, LJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2819 - 2826
  • [2] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    [J]. NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [3] A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease
    Aisen, PS
    Egelko, S
    Andrews, H
    Diaz-Arrastia, R
    Weiner, M
    DeCarli, C
    Jagust, W
    Miller, JW
    Green, R
    Bell, K
    Sano, M
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (02) : 246 - 249
  • [4] AISEN PS, 1994, AM J PSYCHIAT, V151, P1105
  • [5] EFFECT OF LONG-TERM TREATMENT WITH EGB-761 ON AGE-DEPENDENT STRUCTURAL-CHANGES IN THE HIPPOCAMPI OF 3 INBRED MOUSE STRAINS
    BARKATS, M
    VENAULT, P
    CHRISTEN, Y
    COHENSALMON, C
    [J]. LIFE SCIENCES, 1994, 56 (04) : 213 - 222
  • [6] Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
    Brookmeyer, R
    Gray, S
    Kawas, C
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) : 1337 - 1342
  • [7] Plasma total homocysteine and cognitive performance in a volunteer elderly population
    Budge, M
    Johnston, C
    Hogervorst, E
    De Jager, C
    Milwain, E
    Iversen, SD
    Barnetson, L
    King, E
    Smith, AD
    [J]. VASCULAR FACTORS IN ALZHEIMER'S DISEASE, 2000, 903 : 407 - 410
  • [8] Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity:: Implications for neurodegeneration in Alzheimer's disease brain.: A review
    Butterfield, DA
    [J]. FREE RADICAL RESEARCH, 2002, 36 (12) : 1307 - 1313
  • [9] Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease
    Clarke, R
    Smith, AD
    Jobst, KA
    Refsum, H
    Sutton, L
    Ueland, PM
    [J]. ARCHIVES OF NEUROLOGY, 1998, 55 (11) : 1449 - 1455
  • [10] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3